









Mercado
/
Acciones
/
nasdaq-tgtx
/

TG Therapeutics Inc

TGTX

28.860USD

+1.100+3.96%

Cierre 02/06, 16:00（ET）Cotizaciones retrasadas 15 min

4.48BCap. mercado

9.43P/E TTM



TG Therapeutics Inc

28.860

+1.100+3.96%

Descripción general Finanzas Análisis Compañía

Descripción general

Finanzas

Análisis

Compañía

Más Datos de TG Therapeutics Inc Compañía

TG Therapeutics, Inc. is a fully integrated, commercial stage, biopharmaceutical company. The Company is focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. Its clinical drug candidates are Ublituximab IV (anti-CD20 mAb), Ublituximab Subcutaneous (anti-CD20 mAb), Azer-cel, TG-1701 (BTK inhibitor), and TG-1801 (anti-CD47/CD19 bispecific mAb). BRIUMVI is an anti-CD20 monoclonal antibody for the treatment of RMS, which includes clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. TG-1701 is a novel, orally available and covalently bound Bruton’s tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening. TG-1801 is a bispecific CD47 and CD19 antibody. It also evaluates complementary products, technologies and companies for in-licensing, partnership, acquisition, and/or investment opportunities.

Información de TG Therapeutics Inc



Símbolo de cotizaciónTGTX

Nombre de la empresaTG Therapeutics Inc

Fecha de salida a bolsaDec 14, 1995

Director ejecutivoWeiss (Michael S)

Número de empleados338

Tipo de seguridadOrdinary Share

Fin del año fiscalDec 14

Dirección3020 Carrington Mill Blvd., Suite 475

CiudadMORRISVILLE

Bolsa de valoresNASDAQ OMX - NASDAQ BASIC

PaísUnited States of America

Código postal27560-5435

Teléfono18775758489

Sitio Webhttps://www.tgtherapeutics.com/

Símbolo de cotizaciónTGTX

Fecha de salida a bolsaDec 14, 1995

Director ejecutivoWeiss (Michael S)

Ejecutivos de TG Therapeutics Inc



Nombre

Nombre/Posición

Posición

Accionistas

Cambio

Mr. Michael S. Weiss, J.D.

Chairman of the Board, President, Chief Executive Officer

9.78M

+622000.00%

Mr. Sean A. Power

Chief Financial Officer, Treasurer, Corporate Secretary

690.61K

+90000.00%

Mr. Kenneth (Ken) Hoberman

Independent Director

279.65K

+14718.00%

Dr. Yann Echelard

Independent Director

223.82K

-5000.00%

Mr. Daniel Hume, J.D.

Independent Director

192.75K

+14718.00%

Mr. Laurence Neil (Larry) Charney, CPA

Lead Independent Director

179.69K

-43197.00%

Dr. Sagar Lonial

Independent Director

94.06K

-20852.00%

Nombre

Nombre/Posición

Posición

Accionistas

Cambio

Mr. Michael S. Weiss, J.D.

Chairman of the Board, President, Chief Executive Officer

9.78M

+622000.00%

Mr. Sean A. Power

Chief Financial Officer, Treasurer, Corporate Secretary

690.61K

+90000.00%

Mr. Kenneth (Ken) Hoberman

Independent Director

279.65K

+14718.00%

Dr. Yann Echelard

Independent Director

223.82K

-5000.00%

Mr. Daniel Hume, J.D.

Independent Director

192.75K

+14718.00%

Mr. Laurence Neil (Larry) Charney, CPA

Lead Independent Director

179.69K

-43197.00%

Desglose de ingresos

Divisa: USDActualizado: mar., 6 de ene

FY2025Q3

FY2025Q1

FY2024

Por negocioUSD

Nombre

Ganancia

Proporción

Total product revenue, net

159.32M

98.52%

License, milestone, royalty and other revenue

2.39M

1.48%

La empresa aún no ha revelado los datos relevantes.

Por negocio

Por región

Por negocioUSD

Nombre

Ganancia

Proporción

Total product revenue, net

159.32M

98.52%

License, milestone, royalty and other revenue

2.39M

1.48%

Estadísticas de accionistas

Actualizado: mié., 4 de feb

Accionistas

Tipos de accionistas

Accionistas

Proporción

BlackRock Institutional Trust Company, N.A.

11.86%

The Vanguard Group, Inc.

9.95%

Weiss (Michael S)

6.16%

State Street Investment Management (US)

5.10%

ClearBridge Investments, LLC

2.93%

Otro

64.00%

Accionistas

Proporción

BlackRock Institutional Trust Company, N.A.

11.86%

The Vanguard Group, Inc.

9.95%

Weiss (Michael S)

6.16%

State Street Investment Management (US)

5.10%

ClearBridge Investments, LLC

2.93%

Otro

64.00%

Tipos de accionistas

Accionistas

Proporción

Investment Advisor

35.81%

Investment Advisor/Hedge Fund

17.27%

Individual Investor

7.21%

Hedge Fund

7.06%

Research Firm

3.06%

Pension Fund

1.22%

Bank and Trust

0.39%

Family Office

0.22%

Sovereign Wealth Fund

0.06%

Otro

27.71%

Participación institucional



Actualizado: jue., 1 de ene

Periodo del informe

Número de instituciones

Acciones mantenidas

Proporción

Cambio

2025Q4

729

103.02M

64.89%

-17.74M

2025Q3

698

101.46M

63.91%

-17.24M

2025Q2

693

115.94M

73.03%

-21.56M

2025Q1

704

116.82M

73.80%

-25.76M

2024Q4

657

113.87M

72.65%

-36.14M

2024Q3

598

117.83M

76.11%

-20.28M

2024Q2

544

109.58M

70.90%

-28.91M

2024Q1

535

105.41M

68.45%

-29.01M

2023Q4

542

104.64M

69.13%

-36.73M

2023Q3

552

104.67M

69.33%

-30.54M

Actividad de los accionistas



Nombre

Acciones mantenidas

Proporción

Cambio

Cambio %

Fecha

BlackRock Institutional Trust Company, N.A.

18.83M

11.86%

-301.01K

-1.57%

Sep 30, 2025

The Vanguard Group, Inc.

15.49M

9.75%

-288.02K

-1.83%

Sep 30, 2025

Weiss (Michael S)

9.16M

5.77%

-4.67M

-33.77%

Nov 05, 2025

State Street Investment Management (US)

8.10M

5.1%

+482.38K

+6.33%

Sep 30, 2025

ClearBridge Investments, LLC

4.64M

2.93%

+1.59M

+52.15%

Sep 30, 2025

Soleus Capital Management, L.P.

3.84M

2.42%

+1.60M

+71.34%

Sep 30, 2025

Geode Capital Management, L.L.C.

3.44M

2.17%

-46.54K

-1.33%

Sep 30, 2025

Congress Asset Management Company, LLP

1.00M

0.63%

+1.00M

Nov 30, 2025

Hood River Capital Management LLC

1.55M

0.98%

-14.72K

-0.94%

Sep 30, 2025

Pictet Asset Management Ltd.

1.61M

1.01%

-297.94K

-15.62%

Sep 30, 2025

ETFs relacionados



Actualizado: sáb., 6 de dic

Nombre

Proporción

Invesco S&P SmallCap Health Care ETF

2.89%

State Street SPDR S&P Biotech ETF

1.93%

Virtus LifeSci Biotech Products ETF

1.49%

Invesco S&P SmallCap 600 Pure Growth ETF

1.44%

Invesco S&P SmallCap Momentum ETF

1.4%

Direxion Daily S&P Biotech Bull 3X Shares

1.11%

State Street SPDR S&P 600 Small Cap Growth ETF

0.65%

First Trust NASDAQ Pharmaceuticals ETF

0.63%

Principal U.S. Small-Cap ETF

0.62%

Vanguard S&P Small-Cap 600 Growth Index Fund

0.61%

Invesco S&P SmallCap Health Care ETF

Proporción2.89%

State Street SPDR S&P Biotech ETF

Proporción1.93%

Virtus LifeSci Biotech Products ETF

Proporción1.49%

Invesco S&P SmallCap 600 Pure Growth ETF

Proporción1.44%

Invesco S&P SmallCap Momentum ETF

Proporción1.4%

Direxion Daily S&P Biotech Bull 3X Shares

Proporción1.11%

State Street SPDR S&P 600 Small Cap Growth ETF

Proporción0.65%

First Trust NASDAQ Pharmaceuticals ETF

Proporción0.63%

Principal U.S. Small-Cap ETF

Proporción0.62%

Vanguard S&P Small-Cap 600 Growth Index Fund

Proporción0.61%

Dividendos



Un total de 0.00 USD se ha distribuido en dividendos durante los últimos 5 años.

Fecha

Dividendos

Fecha de registro

Fecha de pago

Fecha ex-dividendo

Sin datos

División de acciones



Fecha

Fecha ex-dividendo

Tipo

Relación

Sin datos

Fecha

Fecha ex-dividendo

Tipo

Relación

Sin datos

KeyAI

